10x Genomics Files 8-K on Financials
Ticker: TXG · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: TXG
TL;DR
10x Genomics dropped an 8-K on Oct 9th - check it for financial updates.
AI Summary
On October 9, 2024, 10x Genomics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were disclosed in the provided text, but the filing indicates a report date of October 9, 2024.
Why It Matters
This 8-K filing signals that 10x Genomics is providing updates on its financial performance and condition to the SEC and the public.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine financial information and does not appear to contain any new material risks.
Key Players & Entities
- 10x Genomics, Inc. (company) — Registrant
- October 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by 10x Genomics?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 9, 2024.
What is the SEC file number for 10x Genomics?
The SEC file number for 10x Genomics is 001-39035.
Where is 10x Genomics, Inc. principal executive offices located?
The principal executive offices of 10x Genomics, Inc. are located at 6230 Stoneridge Mall Road, Pleasanton, California 94588.
What is the IRS Employer Identification Number for 10x Genomics?
The IRS Employer Identification Number for 10x Genomics is 45-5614458.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-10-09 16:07:17
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
Filing Documents
- txg-20241009.htm (8-K) — 27KB
- txg-20241009xexx991.htm (EX-99.1) — 18KB
- a10x_logoxhorizontalxfullc.jpg (GRAPHIC) — 152KB
- txg-20241009_g1.jpg (GRAPHIC) — 223KB
- 0001770787-24-000064.txt ( ) — 886KB
- txg-20241009.xsd (EX-101.SCH) — 2KB
- txg-20241009_lab.xml (EX-101.LAB) — 21KB
- txg-20241009_pre.xml (EX-101.PRE) — 12KB
- txg-20241009_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 9, 2024, 10x Genomics, Inc. issued a press release announcing preliminary select third quarter results for the period ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing..
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Press Release dated October 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: October 9, 2024